Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab Safety Syringe Study in Severe Eosinophilic Asthma
NCT03021304Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2017
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of mepolizumab in eosinophilic asthma (EA), sponsored by GSK. Started Feb 2017; status: completed.
02
Drugs
mepolizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT03021304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03021304.